Tempest Therapeutics, Inc. (TPST)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.68
- As of
Kresmion compiles this page from TPST's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Tempest Therapeutics, Inc. (TPST): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-28.
See the full TPST dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TPST on one page. Preview it with sample data, then open it live with a free account.
Preview the TPST dossierActive signals for TPST
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 11.1%, EPS $-0.34 vs $-0.306 estimate
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in TPST
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 22.1% - EPS $-2.07 vs $-2.6571 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 76.3% - EPS $-0.79 vs $-3.3354 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 785.9% - EPS $-2.53 vs $-0.2856 estimate
FREE, NO ACCOUNT
Every signal on TPST, as it fires
New filings, 13F moves and cross asset signals on TPST land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TPST (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 87978U207 · 2026Q2 | $22K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TPST
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TPST against its peers
TPST's return on equity of -393.9% ranks in the 3rd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | TPST | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 667857 | n/a | 10 |
| Gross margin | n/a | 68.4% | n/a | 5 |
| Operating margin | n/a | -3269.4% | n/a | 9 |
| Net margin | n/a | -2777.2% | n/a | 10 |
| Return on equity | -393.9% | -99.3% | 3 | 18 |
| 1 year | -94.1% | -57.5% | 3 | 14 |
Peers (22): AEON, SYBX, HIND, LSTA, PASG, CKDXF, ANEB, INAB, LTRN, PLUR, BIVI, ASBP, GDTC, KTTA, HEPA, TVRD, VTGN, BLRX, PHIO, ICU, CYCN, CLRB. Left out: VICP (period gap), HOOK (period gap), CTXR (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TPST: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow TPST on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to TPST for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.